Apellis turns up mixed results in closely watched eye disease tests. Are the data strong enough for approval?

Kyle Blankenship

Looking to scuffle with rare disease giant and now AstraZeneca subsidiary Alexion, little Apellis scored a breakthrough win earlier this summer for its own complement …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Apellis turns up mixed results in closely watched eye disease tests. Are the data strong enough for approval?

Kyle Blankenship

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Daiichi Sankyo finds successor to late R&D exec; Versant, Novartis' kidney biotech poaches Sana CBO

Apel­lis turns up mixed re­sults in close­ly watched eye dis­ease tests. Are the da­ta strong enough for ap­proval?

Kyle Blankenship

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Dai­ichi Sankyo finds suc­ces­sor to late R&D ex­ec; Ver­sant, No­var­tis' kid­ney biotech poach­es Sana CBO

Apellis turns up mixed results in closely watched eye disease tests. Are the data strong enough for approval?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Daiichi Sankyo finds successor to late R&D exec; Versant, Novartis' kidney biotech poaches Sana CBO